Abstract
Treatment of inoperable non-small cell lung cancer stage III is based on concomitant chemoradiotherapy. However, most patients experience relapse.
Efforts to improve the results have resulted in various combinations of cytostatics administered concurrently with or after radiotherapy, an improvement in the irradiation technique, or an increase in the radiation dose administered. However, only a combination of concomitant chemoradiotherapy with immunotherapy led to a significant improvement in progression-free survival and overall survival.
In the PACIFIC study, durvalumab was given as consolidation therapy after chemoradiotherapy was completed. The results of the study are discussed in detail in the article and represent a change in current clinical practice and a new standard in the treatment of patients with non-small cell lung cancer III. stages.